Surgical vs. Nonsurgical Management of Subretinal Hemorrhage in Neovascular AMD

Managing Subretinal Hemorrhage in Neovascular AMD: A Size-Based Approach to Treatment

Subretinal hemorrhage (SRH) represents a significant clinical challenge for patients diagnosed with neovascular age-related macular degeneration (AMD). Recent clinical insights suggest that the most effective management strategy depends heavily on a single critical factor: the size of the hemorrhage. Rather than a uniform approach, clinicians are increasingly utilizing a size-based classification system to determine whether a patient requires nonsurgical medical management or advanced surgical intervention.

According to J. Fernando Arevalo, MD, PhD, during his presentation at the Retina World Congress, approximately 12% of patients with neovascular AMD eventually develop subretinal hemorrhage. Because the extent of the bleed directly impacts visual prognosis, accurate classification is essential for effective diagnosis and management.

Classifying Subretinal Hemorrhage by Size

To streamline treatment decisions, SRH can be categorized into three distinct groups based on disc diameter (DD). This classification allows clinicians to move away from generalized treatments and toward more targeted, patient-specific care:

• Small SRH: Hemorrhages measuring 1 to less than 4 disc diameters.
• Medium SRH: Hemorrhages measuring at least 4 disc diameters that remain contained within the temporal arcades.
• Massive SRH: Hemorrhages measuring at least 4 disc diameters that extend outside the temporal arcades.

Nonsurgical Management for Small Hemorrhages

For patients presenting with smaller hemorrhages (less than 4 DD), the evidence supports a nonsurgical approach. The primary cornerstone of treatment for these cases is anti-VEGF therapy. By targeting the vascular endothelial growth factor, clinicians can help manage the underlying neovascular processes.

Other conservative options for managing small SRHs include:

• The use of tissue plasminogen activator (tPA) without the need for pars plana vitrectomy.
• Photodynamic therapy.

Surgical Interventions for Medium and Massive Hemorrhages

When a hemorrhage reaches medium or massive proportions, surgical intervention often provides more favorable visual outcomes. For medium-sized hemorrhages, pneumatic displacement (using expansile gas or air) has shown efficacy. For massive hemorrhages, more intensive surgical maneuvers are typically required.

Surgeons may employ pars plana vitrectomy (PPV) combined with several specialized techniques to address larger bleeds, including:

• Macular translocation: Repositioning the macula to improve stability.
• Retinal pigment epithelium (RPE) patch repair: Strengthening the structural integrity of the retina.
• SRH drainage: Directly removing the accumulated blood to reduce pressure and improve the view of the retina.

The Importance of Postoperative Anti-VEGF Therapy

The management of SRH does not end once the surgical or nonsurgical procedure is complete. Clinical reviews indicate that patients who undergo serial anti-VEGF therapy following surgery experience better visual outcomes than those who do not. Adding postoperative anti-VEGF injections appears to be a highly effective method for maintaining visual function over extended periods.

Frequently Asked Questions

How is the size of a subretinal hemorrhage measured?

Clinicians measure the size of the hemorrhage using disc diameters (DD) as a standardized unit of reference to ensure consistent classification.

Is surgery always the first option for AMD-related bleeding?

No. For smaller hemorrhages (under 4 DD), nonsurgical options like anti-VEGF therapy are often the preferred first line of treatment. Surgery is typically reserved for medium or massive hemorrhages to achieve better visual outcomes.

Why is anti-VEGF therapy used after surgery?

Postoperative anti-VEGF injections help maintain visual function over time by managing the neovascular activity that led to the hemorrhage in the first place.